Insider Buying: Septerna, Inc. (NASDAQ:SEPN) CFO Purchases 3,718 Shares of Stock

Septerna, Inc. (NASDAQ:SEPN) CFO Gil M. Labrucherie bought 3,718 shares of the company’s stock in a transaction that occurred on Thursday, February 27th. The shares were bought at an average cost of $5.85 per share, for a total transaction of $21,750.30. Following the completion of the acquisition, the chief financial officer now owns 40,000 shares of the company’s stock, valued at $234,000. This trade represents a 10.25 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Septerna Trading Up 1.8 %

SEPN stock traded up $0.10 during trading on Thursday, hitting $5.80. The stock had a trading volume of 265,272 shares, compared to its average volume of 571,590. The business’s 50-day moving average price is $16.78. Septerna, Inc. has a twelve month low of $4.17 and a twelve month high of $28.99.

Analyst Ratings Changes

A number of brokerages have recently commented on SEPN. Wells Fargo & Company cut shares of Septerna from an “overweight” rating to an “equal weight” rating and dropped their price objective for the stock from $43.00 to $14.00 in a research note on Tuesday, February 18th. TD Cowen began coverage on shares of Septerna in a research report on Tuesday, November 19th. They set a “buy” rating on the stock. Cantor Fitzgerald reiterated an “overweight” rating and issued a $50.00 price objective on shares of Septerna in a research report on Tuesday, February 11th. Finally, JPMorgan Chase & Co. started coverage on Septerna in a research report on Tuesday, November 19th. They set an “overweight” rating and a $38.00 target price on the stock.

Institutional Trading of Septerna

A number of institutional investors have recently made changes to their positions in SEPN. Avoro Capital Advisors LLC acquired a new position in Septerna in the 4th quarter valued at $25,419,000. TRV GP V LLC acquired a new stake in shares of Septerna in the fourth quarter valued at about $142,337,000. TRV GP VI LLC acquired a new stake in shares of Septerna in the fourth quarter valued at about $72,191,000. Vanguard Group Inc. purchased a new position in shares of Septerna in the fourth quarter worth about $22,557,000. Finally, Corebridge Financial Inc. acquired a new position in Septerna during the fourth quarter worth about $212,000.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.